Pacira BioSciences (Pacira BioSciences) EBIT per Share : $1.30 (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Pacira BioSciences EBIT per Share?

Pacira BioSciences's EBIT per Share for the three months ended in Dec. 2023 was $0.53. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.30.

During the past 12 months, the average EBIT per Share Growth Rate of Pacira BioSciences was 10.20% per year. During the past 3 years, the average EBIT per Share Growth Rate was 12.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was 31.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Pacira BioSciences's EBIT per Share or its related term are showing as below:

PCRX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -51.1 Med: 22.05 Max: 89.6
Current: 12.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Pacira BioSciences was 89.60% per year. The lowest was -51.10% per year. And the median was 22.05% per year.

PCRX's 3-Year EBIT Growth Rate is ranked better than
56.69% of 852 companies
in the Drug Manufacturers industry
Industry Median: 7.95 vs PCRX: 12.50

Pacira BioSciences's EBIT for the three months ended in Dec. 2023 was $36.4 Mil.

Pacira BioSciences EBIT per Share Historical Data

The historical data trend for Pacira BioSciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacira BioSciences EBIT per Share Chart

Pacira BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.27

1.00

1.87

1.05

1.52

Pacira BioSciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.18	-0.39	0.79	0.37	0.53

Pacira BioSciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Pacira BioSciences's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	79.011	/	51.979
=	1.52

Pacira BioSciences's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	36.423	/	68.887
=	0.53

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.30

Pacira BioSciences (NAS:PCRX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Pacira BioSciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Pacira BioSciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacira BioSciences (Pacira BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pacira BioSciences Inc (NAS:PCRX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

82P:Germany

Address

5401 West Kennedy Boulevard, Suite 890, Tampa, FL, USA, 33609

Website

https://www.pacira.com

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has launched EXPAREL which utilizes DepoFoam, a product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time.

Executives

Marcelo Bigal	director	C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Abraham Ceesay	director	C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830
Alethia Young	director	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Michael J. Yang	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Roy Winston	officer: Chief Clinical Officer	C/O PACIRA BIOSCIENCES, INC,, 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA FL 33609
Lauren Bullaro Riker	officer: Executive Director, Accounting	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Kristen Marie Williams	officer: CAO and General Counsel	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Mark A. Kronenfeld	director	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 100, PARSIPPANY NJ 07054
Daryl Gaugler	officer: Chief Operating Officer	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Reinhart Charles A. Iii	officer: Chief Financial Officer	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Ellis Ronald J. Jr.	officer: Chief Strategy Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Max Reinhardt	officer: President	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
David M Stack	director, officer: President and CEO	THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Dennis Mcloughlin	officer: Chief Commercial Officer	C/O PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Jonathan Slonin	officer: Chief Clinical Officer	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054